(
A) Identifying TPL-N terminal domain interactor proteins through yeast two hybrid screening identifies TPL as a problematic bait protein as it may silence the activation despite successful binding of a prey protein (see second row from bottom where N188 and MED21 show very weak reporter activity on 3AT). 3AT: 3-amino-1,2,4-triazole. Plates were measured after 3 days to allow TPL-MED21 interactions to grow. (
B) Identifying TPL-N terminal domain interactor proteins through cytoplasmic split ubiquitin protein interaction assay. We tested the N-terminal and C-terminal portions of MED13 separately and divided the coding sequence at amino acid 967 (MED13N = aa1-967, MED13C = aa968-1908). Each bait tested is the
Arabidopsis homolog cloned from cDNA from the Col-0 accession, with the exception of
AtMED13, which was synthesized de novo via Twist (
https://www.twistbioscience.com/). Plates were scanned at 3 days after plating to allow weaker interactions to develop if they were present. (
C) TPL interacts with MED21 through an interaction within Helices 8–9. Plates were scanned at 2 days after plating. (
D) The Helix 8 Quadruple mutation (V145A, E146A, K148A, K149A) does not affect AtMED10B binding to TPL. Plates were scanned at 3 days after plating. (
B–D) The relative position of the N-terminal portion of ubiquitin (Nub) is indicated for each bait protein.